35 results about "Dextran Sulfate Sodium" patented technology

In one aspect, a demulsification additive includes a separation-promoting agent and a solvent. In another aspect, a demulsification additive includes a separation-promoting agent and a demulsifier or demulsifier intermediate. In another aspect, a method for separating crude oil from water includes introducing the water to the cmde oil, providing a demulsification additive that includes a separation-promoting agent, and contacting the water and the crude oil with the demulsification additive. In one embodiment, the separation-promoting agent is selected from the group consisting of dextran sulfate sodium salt, polyvinyl pyrrolidone functionalized with sodium salt of chloroacetic acid, poly(ethyleneglycol)-b(propyleneglycol)-b(ethyleneglycol) block copolymer, polyvinyl pyrrolidone functionalized with propyl sulfonate, sulfonated polyether ether ketone polymer, polyvinyl pyrrolidone functionalized with bromohexane, polyvinyl pyrrolidone functionalized with iodododecane, and combinations thereof.

The invention discloses an inflammatory bowel disease model, a construction method and application thereof and a drug evaluation method based on the inflammatory bowel disease model, and belongs to the technical field of inflammatory bowel disease model construction. A highly bionic intestinal crypt-villus three-dimensional structure is formed based on self-organization of an intestinal cell line C2BBe1, the intestinal crypt-villus three-dimensional structure and a DMEM complete medium containing dextran sulfate sodium are added into an upper chamber of a double-layer culture chamber Transwell, the DMEM complete medium is added into a lower chamber of the double-layer culture chamber Transwell, culture is performed for 2 days, and the inflammatory bowel disease model is obtained. The method takes effect quickly and is highly simulated, the obtained model can simulate the space-time dynamic development process of intestinal inflammation molecular characteristics, and the natural recovery model and the drug treatment model constructed based on the model can provide a brand new platform for researching an inflammation regression mechanism and a drug intervention effect.

The invention relates to a rapid film-forming repair composition as well as a preparation method and application thereof. The rapid film-forming repair composition comprises a rapid film-forming repair component, a film softener, a pH regulator, a preservative and water, the film-forming repairing component is prepared from water temple porphyra polysaccharide, galactose araban and dextran sulfate sodium. Wherein the water temple laver polysaccharide, the galactose araban and the dextran sulfate sodium are combined for use and can interact, the synergistic promotion effect is achieved on the related skin improvement effect, and particularly, the effective components in the product can be promoted to rapidly form a film after being used, so that the skin is efficiently conditioned and repaired, and the skin quality is improved. The rapid film-forming repair composition provided by the invention also can relieve skin inflammation and redness, promote tissue regeneration and the like, is very suitable for skin care products, and is mild, non-irritant and good in stability.

The invention discloses an inflammatory bowel disease treatment method based on intestinal flora regulatory gene CD24 expression. According to the method, expression or functions of CD24 in host intestinal epithelial cells are up-regulated, the intestinal flora structure is adjusted, and intestinal inflammation is relieved. CD24 up-regulation can be realized by transfecting a CD24 gene overexpression vector, applying a transcription factor or a small molecule agonist or enhancing the activity of an endogenous gene by utilizing a gene editing technology. The CD24 is regulated and controlled, so that the proportion of the phylum firmicalis to the phylum bacteroides can be normalized, the enrichment of short-chain fatty acid producing flora is promoted, the activation of NF-kappa B and NLRP3 inflammasomes is inhibited, and the intestinal barrier function is enhanced. The DSS induced colitis model is established by drinking a 2-5% dextran sodium sulfate solution by a mouse, and simulates the pathological characteristics of human ulcerative colitis. Intervention modes include oral administration, enema or nanoparticle targeted delivery of the CD24 agonist pharmaceutical composition. The invention provides a new strategy for the treatment of inflammatory bowel diseases, especially ulcerative colitis, and has obvious dual curative effects of anti-inflammation and flora regulation.

The invention discloses a chitosan non-binding bilirubin microsphere as well as a preparation method and application thereof. The chitosan non-binding bilirubin microspheres are prepared by taking chitosan as a delivery carrier and taking chitosan and bilirubin as main raw materials through an emulsion reaction and a cross-linking reaction in sequence. Chitosan (CIS) is selected as a carrier for delivering unbound bilirubin (UCB), and the chitosan unbound bilirubin microspheres are prepared through an emulsion reaction and a cross-linking reaction, so that the UCB is more safely and efficiently fed into the intestinal tract to reach an inflammation part, and experiments prove that the UCB can be used for preparing the unbound bilirubin microspheres. The chitosan non-binding bilirubin microsphere has a remarkable protective effect on the intestinal immune function, microbiota disorder and barrier function of a dextran sodium sulfate (DSS) induced ulcerative colitis (UC) mouse.

This invention discloses the application of chestnut total burr ethanol extract in the preparation of anti-colitis drugs. In this invention, the chestnut total burr ethanol extract with anti-colitis properties is obtained by extracting chestnut total burrs with 70% ethanol. This chestnut total burr ethanol extract inhibits the production of LPS-induced pro-inflammatory mediators (NO) and pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) without cytotoxicity; it has a significant inhibitory effect on dextran sulfate sodium-induced colitis in mice, including slowing down weight loss, reducing mouse DAI scores, alleviating colonic tissue damage, downregulating the levels of IL-6, IL-1β, TNF-α, and MDA in mouse colonic tissue and serum, and enhancing the activities of CAT and SOD in mouse colonic tissue and serum. Therefore, the chestnut total burr ethanol extract has significant anti-inflammatory effects both in vivo and in vitro, and can be used to treat colitis.

The invention belongs to the technical field of biomedicine, and particularly relates to application of ME1 in preparation of a medicine for preventing and / or treating inflammatory bowel diseases. The invention discloses an application of an ME1 inhibitor in preparation of drugs for preventing and / or treating inflammatory bowel diseases, and an application of a substance for detecting ME1 in preparation of drugs for diagnosing or detecting inflammatory bowel diseases. The action effect of ME1 * in disease treatment is evaluated through a mouse IBD model induced by dextran sodium sulfate DSS and trinitrobenzene sulfonic acid TNBS, so that a new strategy and method are provided for clinical intervention of IBD. In addition, the invention also clarifies the application of the ME1 as a high-specificity biomarker in IBD diagnosis, and further expands the comprehensive value of the ME1 in disease prevention and treatment.

The present invention relates to a composition for preventing, alleviating or treating fibrosis, the composition comprising bentonite as an active ingredient. Bentonite is highly effective in reducing a disease activity index, inhibiting shortening of colon length, regulating the expression level of a gene related to intestinal fibrosis, reducing a collagen deposition site in intestinal tissue, reducing the expression level of fibronectin and collagen proteins in intestinal tissue in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of ɑ-smooth muscle actin (ɑ-SMA) and collagen proteins in an intestinal fibrosis cell model induced by TGF-β, and is thus expected to be useful as a composition for preventing, alleviating, or treating intestinal fibrosis.

The present application discloses isoschaftoside and its compositions and uses. Experiments have proven that isoschaftoside can significantly improve dextran sulfate sodium-induced colitis in mice, specifically manifested as significantly alleviating the weight loss and shortening of colon length caused by the model establishment; significantly reducing the disease activity index and spleen weight of mice; significantly alleviating the pathological changes in the colon tissues of mice, including reducing inflammatory cell infiltration, restoring the crypt structure of the tissue and the number of intestinal glands, and having significant anti-ulcerative colitis activity, showing good application prospects in the preparation of drugs for treating ulcerative colitis.

The invention discloses kombucha capable of improving ulcerative colitis as well as a preparation method and application of the kombucha, and belongs to the technical field of fermented foods. The preparation method comprises the following steps: S1, inoculating 5% of kombucha pellicle into black tea sugar tea water for fermentation culture, and activating to prepare Kangpu tea fermentation liquor; and S2, inoculating the Kangpu tea fermentation liquor in the S1 into black tea sugar tea water according to the inoculum size of 1%, and performing fermentation culture for 4 days to obtain the kombucha. According to the kombucha capable of improving ulcerative colitis as well as the preparation method and the application of the kombucha, the kombucha can effectively relieve colon injury caused by dextran sulfate sodium (DSS), regulate the intestinal barrier and inflammation level and effectively relieve colon oxidative injury at the same time.

The invention provides application of a five-membered heterocycle substituted styrene derivative in preparation of a medicine for treating ulcerative colitis and / or improving intestinal barrier function and the medicine. The five-membered heterocycle substituted styrene derivative disclosed by the invention not only can be used for remarkably relieving symptoms of mouse ulcerative colitis (UC) induced by dextran sodium sulfate (DSS), but also is safe and free from toxic and side effects. The invention also verifies that the five-membered heterocycle substituted styrene derivative has an anti-inflammatory effect, can improve the barrier function of the intestinal tract, and can inhibit the increase of the permeability of the intestinal tract caused by ulcerative colitis. According to the application, the treatment effect of the five-membered heterocycle substituted styrene derivative on ulcerative colitis and the improvement effect on the intestinal barrier function are defined from the action mechanism, and the activation of an aromatic receptor can also improve the intestinal immune function; the invention provides a new therapeutic target and theoretical basis for fundamental research and clinical treatment of ulcerative colitis.

The present invention relates to a sanguisorba officinalis polysaccharide, its preparation method and uses. In the sanguisorba officinalis polysaccharide of the present invention, by weight percentage, the neutral sugar content is 79% - 85%, the uronic acid content is 13% - 19%, and the protein content is 1% - 4%. The composition of the polysaccharide includes mannose, rhamnose, galacturonic acid, galactose, xylose and arabinose. In vitro and in vivo experiments have proved that the sanguisorba officinalis polysaccharide can significantly inhibit the expression of inflammation-related factors in the enteritis cell model and relieve the symptoms of dextran sulfate sodium-induced acute colitis in mice, including the weight loss of mice, the increase of spleen weight index, the reduction of colon length and the intestinal structure damage. And it has no effect on the growth viability of normal intestinal epithelial cells in vitro and has no toxic effect on the important organs of mice in vivo, with high safety. Therefore, the polysaccharide has the potential to treat gastrointestinal inflammatory diseases and is expected to become a candidate carbohydrate drug for treating gastrointestinal inflammatory diseases.

The invention relates to the field of biological medicine, and particularly provides application of a membrane protein CMTM3 as a drug target for treating inflammatory bowel disease and related colorectal cancer. The invention discovers and verifies that deletion of Cmtm3 can protect mice from AOM / DSS induced colorectal cancer (CAC) for the first time. A further research result proves that the endothelial cell-derived CMTM3 promotes the development of enteritis. The Cmtm3 gene knockout and the imatinimex can regulate the vascular permeability in a targeted manner and have a considerable curative effect. The application also discloses that the CMTM3 promotes vascular permeability to aggravate enteritis by stabilizing CLTC and increasing gridding protein mediated endocytosis of VE-cadherin in endothelial cells, thereby promoting the development of inflammation-related colon cancer, which indicates that the CMTM3 can be used as a potential therapeutic target for enteritis and colon cancer (CAC).

The application discloses a method for preparing high-value cellobiose from a medicine and food homologous Radix Millettiae and application of the high-value cellobiose. The method comprises the following steps: extracting cellulose from Radix Millettiae; optimizing a beta-glucanase enzymolysis process by using a response surface method; after the enzymolysis liquid is subjected to selective removal of glucose through yeast fermentation, the high-value cellobiose product is obtained through acetone precipitation and freeze-drying. The process condition is mild and environment-friendly, high-value utilization of agricultural waste is realized, the obtained cellobiose product has high purity, and an economic and effective approach is provided for large-scale production of cellobiose. Animal experiments prove that the cellobiose product has a significant relieving effect on colonitis induced by dextran sulfate sodium in mice, can effectively improve disease symptoms, reduce oxidative stress, repair intestinal barrier and regulate inflammatory response, and has a good application prospect in preparation of functional food or medicine for relieving colonitis and high-value utilization of Radix Millettiae.

The invention relates to core components from five strains of independently isolated, identified and patent-deposited probiotics and fermentation metabolites thereof (postbiotics), as well as their use as a protector in alleviating dextran sulfate sodium (DSS) induced-colitis in mice. Further disclosed the mechanism of the probiotics and fermentation metabolites thereof (postbiotics) to alleviate colitis in mice.

The invention provides a preparation method of sodium dextran sulfate and application of the sodium dextran sulfate in red fading cosmetics, and relates to the technical field of catalytic synthesis. The preparation method comprises the following steps: S1, mixing glucan with the molecular weight of 1.5-30 thousand, beta-glucanase and a ZSM-5 molecular sieve to obtain pretreated glucan; s2, the pretreated dextran, a sulfonating reagent and a catalyst are mixed for a reaction, and dextran sulfate is obtained; s3, enabling the dextran sulfate to react with sodium salt, so as to obtain the dextran sulfate sodium. According to the specific preparation method disclosed by the invention, high-purity dextran sodium sulfate with specific molecular weight is obtained through specific raw materials, reaction conditions, refining steps, refining solvents and the like, and the stability is improved.

Provided is a method for preventing and alleviating inflammatory bowel disease by administering a composition including puer tea extract as an active ingredient to a subject in need thereof. Puer tea extract of the present disclosure showed an effect of improving damaged colonic tissue in a mouse model of acute ulcerative colitis induced by dextran sulfate sodium (DSS), and showed an inhibitory effect on clinical symptoms of the disease activity index (DAT) of weight loss, diarrhea, and rectal bleeding. In addition, puer tea extract inhibited the expression of inflammatory cytokines TNF-α and IL-6 in the colonic tissue and inhibited the inflammatory response through inhibition of the activity of NF-κB, an anti-inflammatory mechanism. In addition, the DPPH free radical and ABTS free radical scavenging ability increased proportionally as the concentration of puer tea extract increased at the cellular level, and COX-2 expression was inhibited in LPS-activated macrophages.

Therapeutic agents such as mRNA fragments are delivered to a patient to treat peripheral nerve system injuries via functionalized fiber networks. The fiber networks are electrospun from poly(L-lactic acid), producing a hollow conduit of aligned fibers. The networks are functionalized with an anionic layer, e.g., dextran sulfate sodium salt (DSS), poly(3,4-dihydroxy-L-phenylalanine) (pDOPA). mRNA complexes including a cationic liposomal transfection portion and an mRNA portion, such as Ψ-modified mRNA encoding neurotrophin-3 (NT-3), are immobilized thereon. The fiber networks are positioned to bridge a peripheral nerve gap in the patient. These networks upregulate secretion of expressed oligopeptides, e.g., NT-3, by surrounding cells, and thus enhance neurite outgrowth. The networks serve as versatile non-viral mRNA delivery platforms. The mRNA transcript, gene delivery vehicle, and surface coatings can be modified to regulate different desired proteins, optimize transfection efficiency, enable targeted delivery, and tune loading efficiency and release kinetics.

The invention provides application of earthworm protein hydrolysate in preparation of an intestinal mucosa barrier protective agent, and belongs to the technical field of earthworm deep processing. The invention provides an application of earthworm protein hydrolysate (EWPH) in preparation of an intestinal mucosa barrier protective agent. EWPH treatment is given to a dextran sulfate sodium salt (DSS)-induced mouse intestinal mucosa injury model, and the effect and the treatment mechanism of the EWPH treatment are evaluated. Results show that the EWPH has a protective effect on intestinal mucosal injury, and the mechanism of the EWPH relates to inhibition of activation of a TLR4-MAPK / NF-kappa B pathway, inhibition of inflammatory cell infiltration, adjustment of inflammatory cytokines and the like. Therefore, the invention proves that the EWPH can be used as an intestinal mucosa barrier protective agent, which also points out a specific promising direction for the production and high-valued processing of EWPH-related bioactive peptides.

Use of Bifidobacterium animalis subsp. lactis BX-245 in the preparation of a probiotic preparation for relieving inflammatory bowel disease, characterized in that the Bifidobacterium animalis subsp. lactis BX-245 is deposited in the China General Microbiological Culture Collection Center, with the deposit number: CGMCC No. 26973; the purpose of this invention is to explore the alleviating effect of Bifidobacterium animalis subsp. lactis BX-245 on dextran sulfate sodium (DSS)-induced IBD mice. Six-week-old male C57BL / 6J mice with normal food intake and water intake were randomly divided into a normal group (NC group), a model group (IBD group), a regular yogurt group (FM group), a Bifidobacterium animalis subsp. lactis BX-245 powder group (BX-245 group), and a BX-245 yogurt group (BFM group). The alleviating effect of Bifidobacterium animalis subsp. lactis BX-245 and its fermented milk on the symptoms of murine inflammatory bowel disease was evaluated by body weight changes, immune factors, targeted metabolomics, and metagenomics, aiming to provide data support for the application of Bifidobacterium animalis subsp. lactis BX-245 in products.

The present invention belongs to the field of medicine and discloses the use of a trifluoromethyl vinyl ester compound in the preparation of a drug for treating ulcerative colitis. The compound has the chemical structure shown in Formula 1: The present invention reveals that the compound has the effect of treating ulcerative colitis. The present invention uses a mouse ulcerative colitis model and an LPS-induced macrophage RAW264.7 inflammation model to observe a series of tests such as the therapeutic effect of the novel trifluoromethyl vinyl ester compound BLF-16 on ulcerative colitis, and explores the therapeutic effect of compound BLF-16 on dextran sulfate sodium-induced ulcerative colitis in mice. It is first revealed that compound BLF-16 can treat ulcerative colitis and has good medicinal prospects.

The present invention relates to a composition for preventing, alleviating, or treating depression or anxiety disorder, the composition comprising a zeolite as an active ingredient, wherein the zeolite is excellent in increasing activity by alleviating depression or anxiety disorder in open-field tests and light-dark tests using a colitis animal model induced by dextran sulfate sodium salt (DSS), and is thus expected to be useful as a composition for preventing, alleviating, or treating depression or anxiety disorder.

The present invention provides Kazachstania unispora KU2, selenium-enriched Kazachstania unispora and their applications, relating to the technical field of functional microbial fermentation. The present invention provides a strain of Kazachstania unispora KU2 with a preservation number of CCTCC NO: M2023410. The Kazachstania unispora provided by the present invention has good selenium enrichment ability, especially high organic selenium enrichment ability. The selenium-enriched Kazachstania unispora provided by the present invention comprises the Kazachstania unispora KU2 and selenium. The selenium-enriched Kazachstania unispora provided by the present invention has a high selenium content and a high organic selenium content, and has a significant alleviating effect on colitis, especially colitis induced by dextran sulfate sodium and / or patulin, providing a reference for the development and mechanism research of anti-colitis drugs; moreover, it can also meet the requirements of organic environmental-friendly foods and feeds.

The present invention relates to a composition for preventing, alleviating, or treating inflammatory bowel disease, the composition comprising a Cynomorium songaricum extract as an active ingredient. In an animal model of inflammatory bowel disease induced by dextran sulfate sodium (DSS), the Cynomorium songaricum extract increases body weight reduced due to DSS and reduces increased colon weight, and in particular, a mixture of the Cynomorium songaricum extract and a Gleditsia sinensis sting extract more significantly reduces a disease activity index increased by DSS administration than the Cynomorium songaricum extract or the Gleditsia sinensis sting extract alone. Thus, the composition can be highly effectively used in health functional foods or medicines for preventing, alleviating, or treating inflammatory bowel disease.

The application relates to the technical field of ulcerative colitis prevention and treatment, and particularly relates to application of avicularin in preparation of ulcerative colitis prevention and treatment drugs. Avicularin can effectively improve ulcerative colitis of mice caused by dextran sulfate sodium (DSS), can not only improve colon injury and reduce DAI index, but also can reduce expression of inflammatory cytokines and increase expression of intestinal mucosal barrier related proteins.

The invention provides application of gentisic acid in preparation of a medicine for treating inflammatory bowel diseases. The invention finds that gentisic acid has better improvement and treatment effects on inflammatory bowel diseases (especially ulcerative colitis) for the first time. The gentisic acid provided by the invention can remarkably improve symptoms of mouse acute ulcerative colitis induced by sodium dextran sulfate (DSS), for example, weight loss is relieved, the disease active index is reduced, colon shortening is relieved, and intestinal pathological injury is improved; and the treatment effect is possibly related to inhibition of Th1 cell differentiation and reduction of interferon-gamma (IFN-gamma) secretion by the gentisic acid. The invention discloses the effect of the natural compound gentisic acid in treating the inflammatory bowel disease, and expands the new application of the natural compound gentisic acid in pharmacology, new drug research and development and clinical treatment.

The invention provides a non-oxygen dependent type photodynamic nano material with a function of targeting M1 macrophages and application of the non-oxygen dependent type photodynamic nano material. The non-oxygen dependent type photodynamic nano material comprises chitosan nano particles coated with porphyrin supramolecules and dextran sulfate sodium salt. The material regulates LSG excessive activation through a neural immune strategy of M1 macrophages in selective apoptosis left stellate ganglion (LSG), so as to prevent and treat malignant arrhythmia after myocardial infarction.

A resin is formed through a ring-opening reaction of dextran sulfate sodium salt and a modified polyether sulfone. The modified polyether sulfone is formed by a reaction of polyether sulfone and an epoxy compound containing a carbon-carbon double bond. The resin may serve as an adsorption material, which can be a porous film or a porous hollow fiber. The adsorption material can be in contact with blood to lower LDL-C concentration in the blood.

The invention relates to application of licraside and a pharmaceutical composition for preventing or treating intestinal epithelial cell injury, and relates to the field of drug development. The licraside is used for preparing a medicine for preventing or treating intestinal epithelial cell injury. The Licraside disclosed by the invention can be used for repairing intestinal epithelial cell injury and has a protective effect on a dextran sodium sulfate induced cell inflammation model; the blank of existing licraside research is filled, and an experimental basis is provided for further development of new drugs.

The present invention relates to the field of medical testing technology, and more particularly to a sample diluent for eliminating differences between different sample tubes, and a preparation method and application thereof. The sample diluent is a buffer solution containing 0.5 wt% to 2 wt% dextran sulfate sodium salt; the buffer solution is composed of Bis-Tris buffer and MES buffer. The sample diluent of the present invention is applied to immunoassays to effectively eliminate differences in sample results between different blood collection tubes, thereby enriching the sample types applicable to the kit and facilitating clinical use.